Emma Walmsley's decision to step down as chief executive officer of GSK Plc brings to a close a nearly nine-year tenure, leaving the FTSE 100 with just nine female CEOs. Her departure comes as GSK works to strengthen its drug pipeline and offset the upcoming loss of patent protection on its top-selling HIV drug, dolutegravir.